Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Unicycive Therapeutics, Inc.

Contributing Author

Recent Articles by Unicycive Therapeutics, Inc.

Oct-21
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 UNCY GlobeNewswire
Oct-01
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors UNCY GlobeNewswire
Sep-29
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate UNCY GlobeNewswire
Sep-01
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference UNCY GlobeNewswire
Aug-12
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update UNCY +7.80% GlobeNewswire
Jun-30
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA) UNCY -39.09% GlobeNewswire
May-12
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update UNCY GlobeNewswire
Apr-09
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference UNCY GlobeNewswire
Mar-30
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update UNCY GlobeNewswire
Feb-04
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit UNCY -5.92% GlobeNewswire
Jan-29
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission UNCY GlobeNewswire
Jan-29
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission UNCY GlobeNewswire
Dec-29
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) UNCY GlobeNewswire
Nov-25
Unicycive Therapeutics to Participate in Upcoming Investor Events in December UNCY GlobeNewswire
Nov-12
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update UNCY +7.31% GlobeNewswire
Nov-03
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference UNCY -6.53% GlobeNewswire
Oct-30
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference UNCY GlobeNewswire
Oct-28
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End UNCY -9.92% GlobeNewswire
Aug-26
Unicycive Therapeutics to Participate in Upcoming Investor Events in September UNCY GlobeNewswire
Aug-18
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease UNCY -13.19% GlobeNewswire
Aug-14
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire
Jul-24
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology UNCY +5.21% GlobeNewswire
Jul-08
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement UNCY +5.97% GlobeNewswire
Jul-07
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference UNCY GlobeNewswire
Jun-30
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY -29.85% GlobeNewswire
Jun-17
Unicycive Therapeutics, Inc. Announces Reverse Stock Split UNCY -8.96% GlobeNewswire
Jun-10
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY -40.88% GlobeNewswire
May-22
Unicycive Therapeutics to Present at Upcoming Investor Conferences UNCY GlobeNewswire
May-21
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders UNCY -5.00% GlobeNewswire
May-14
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update UNCY -7.83% GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)